STOK — Stoke Therapeutics, Inc.

Is STOK overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of November 17, 2026

Stoke Therapeutics, Inc. (STOK) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $26.63. The rating moved from Neutral to Oversold on November 17, 2026.

See all oversold Healthcare stocks →

AI analysis

Stoke Therapeutics is a clinical-stage biotech with a pipeline targeting genetic and rare-disease indications. Valuation is driven by clinical progress and partnership/exit optionality rather than commercial revenue, leaving performance highly dependent on upcoming data and financing outcomes. Short-term market caution and defensive flows may mute upside into the next session, but sector consolidation and large-pharma interest in specialty assets create a meaningful upside pathway if programs deliver positive readouts or attract collaboration offers. Primary vulnerabilities are binary clinical and regulatory outcomes, the need for near-term capital, and competitive advances in adjacent modalities. Investors should weigh the asymmetric upside of successful catalysts against high execution and dilution risk.

Key factors

  • Clinical-stage pipeline focused on genetic/rare-disease targets with near- to mid-term catalysts (data readouts and regulatory interactions) that can drive binary upside
  • Proprietary therapeutic platform and differentiated mechanism that could command premium pricing or partnership interest if clinical proof-of-concept is achieved
  • Sector M&A and partnering tailwinds: large-cap pharma appetite for specialty/rare-disease assets increases acquisition or collaboration optionality
  • Current market caution and defensive flows may compress short-term performance, creating buying opportunities ahead of positive catalysts
  • Limited or no commercial revenue; valuation driven primarily by R&D progress and sentiment around upcoming milestones

Risks

  • Clinical trial failure or disappointing data for lead programs, which would materially reduce valuation
  • Cash runway and financing risk: need for equity raises could cause dilution if partnerships or milestone payments do not materialize
  • Regulatory setbacks or slower-than-expected approval timelines for novel modalities in rare disease
  • Competitive risk from other genetic/oligonucleotide/gene‑therapy approaches advancing in the same indications
  • Market and macro risk: risk‑off investor environment and volatility in biotech sector can amplify downside on negative news
  • Reimbursement and pricing pressure for high-cost orphan therapies could limit commercial upside

See today's live rating, score and targets

Members see the live hourly rating for STOK — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.